Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified. All variables were collected through retrospective review of medical records of patients dermatology unit are made.
Study Type
OBSERVATIONAL
Enrollment
70
Hospital Clinic
Barcelona, Barcelona, Spain
H.U. Reina Sofía
Córdoba, Córdoba, Spain
Hospital de Andújar
Jaén, Jaén, Spain
Hospital la Paz
Madrid, Madrid, Spain
H.U. Virgen de la Victoria
primary ineffectiveness in patients with etanercept treatment
Number of participants not achieve PASI 50 response at 12 weeks
Time frame: 24 weeks
Secondary ineffectiveness in patients with etanercept treatment
Number of participants with Poor adherence to treatment with etanercept",
Time frame: 24 weeks (duration of treatment with etanercept)
Ineffectiveness of treatment in localized lesions in patients with etanercept treatment
Despite having achieved a good response PASI no improvement in critical injuries
Time frame: 24 weeks(duration of treatment with etanercept)
primary ineffectiveness in patients with etanercept treatment
Number of participants not achieve PASI 75 response at 24 weeks
Time frame: 24 weeks
Number of participants with adverse events during treatment with etanercept
Time frame: 24 weeks
Number of participants with disease remission
Time frame: 24 weeks
number of participants with Poor adherence to treatment with etanercept
Time frame: 24 weeks
number of participants with Conditions requiring hospitalization and / or surgery
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Málaga, Málaga, Spain